Tests chemotherapy combinations for olfactory neuroblastoma, a tumor in the nose
Compares two chemotherapy combinations in adults with olfactory neuroblastoma.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Where in China
- Eye ENT Hospital of Fudan UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hongmeng Yu
- Trial code
- NCT06255210
- Record updated
- 13 February 2024
- Original description
The goal of this clinical trial is to learn about the induction chemotherapy efficacy in olfactory neuroblastoma. The main question it aims to answer is: wether olfactory neuroblastoma patients with different pathology subtypes apply to different induction chemotherapy schemes. Participants will be treated with different chemotherapy schemes, to evaluate the tumor remission rate and long term survival.Read full original descriptionShow less
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma: a Prospective Umbrella Clinical Study
The goal of this clinical trial is to learn about the induction chemotherapy efficacy in olfactory neuroblastoma. The main question it aims to answer is: wether olfactory neuroblastoma patients with different pathology subtypes apply to different induction chemotherapy schemes. Participants will be treated with different chemotherapy schemes, to evaluate the tumor remission rate and long term survival.
Inclusion: Patients with pathologically confirmed olfactory neuroblastoma; Age ≥ 18 years old; Dulguerov stage T2-T4; Patients who signed the informed consent forms; No distant metastasis.
Exclusion: Patients with uncontrolled concurrent diseases that the researchers believe will interfere with treatment; Severe neurological or mental illness, including dementia and seizures; Uncontrolled active infection; Any situation in which the patient may interfere with the compliance or safety during the study; Pregnant or lactating women; Persons without personal freedom and independent capacity for civil conduct; Other situations that are not suitable for joining the group.